01789nas a2200289   4500000000100000008004100001260001700042653001600059653002400075653001100099653001100110653002300121653002400144653002500168653000900193100001300202700001600215700001500231700001400246700001500260245006800275300001100343490000700354050003200361520109200393022001401485       1999                            d  c1999 Jul-Sep10aClofazimine10aDouble-Blind Method10aFemale10aHumans10aLeprostatic Agents10aLeprosy, Borderline10aLeprosy, Tuberculoid10aMale1 aKatoch K1 aNatarajan M1 aKatoch V M1 aSingh H B1 aBhatia A S00aChemotherapy trial in paucibacillary leprosy using clofazimine.  a311-240 v71  aInfolep Library - available3 a<p>In a double blind study, 300 PB patients (smear negative, indeterminate, tuberculoid and borderline tuberculoid) were randomly allotted to two regimens, the control subjects (150 patients) receiving the standard WHO multidrug regimen of six doses of once a month rifampicin with daily dapsone therapy for six months, while the study group (150 patients) receiving 50 mg of clofazimine daily for six months in addition to the WHO regimen. After stoppage of therapy all the patients were followed up on placebo. The regimens were well tolerated. In 7.5% of patients on clofazimine containing regimen, the lesions showed persisting activity at the time of stoppage of therapy, compared with 16% on the control regimen. This activity subsided spontaneously, more rapidly, in the study group (80% compared with 30% in the control group) in six months. Two patients in the control group and one patient in the study group developed late reaction. There were no relapses in the study group, whereas, two patients have relapsed in the control group during a follow-up of 2.5 to 3.5 years.</p>  a0254-9395